季鸣，副研究员，北京大学药学本科，北京协和医学院分子生物学和生物化学硕士，药理学博士，2018年奥地利科学院生物技术研究所Visiting Scientist。
曾先后任职于北京依格斯医疗科技有限公司、辉瑞制药有限公司，负责多个新药在中国临床开发和上市注册，涉及治疗领域包括心血管药物、泌尿系统药物、妇科药物、眼科药物、抗感染和抗艾滋病毒药物等。
现就职于中国医学科学院药物研究所药理室，先后主持和参与多个国家自然基金、院校级基金，发表SCI文章20多篇，申请专利20多个，参与4个1类新药研发。

主要研究方向为肿瘤药理和抗肿瘤小分子药物开发，涉及细胞毒类、分子靶向和肿瘤免疫治疗药物。
（1）肿瘤新靶点的发现：与国内外研究机构展开合作，针对肿瘤新靶点如DDX3开展作用机制研究，在此基础上针对新靶点开展药物研发。
（2）生物标志物的寻找：立足于在研药物，通过寻找生物标志物，为药物开发提供指导，如发现RAS突变是决定口服微管/STAT3双靶点抑制剂IMM-H020疗效的重要标志物、肿瘤脂肪酸合成过度活化可能是导致PARP抑制剂疗效不佳的重要因素等。
（3）独特技术平台的建立：建立了国内具有独特优势的脑部肿瘤/肿瘤脑转移治疗药物原位药效评价平台。利用该平台，先后推进了药物研发。

1. A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Ming Ji#, Dongjie Wang#, Songwen Lin, Chunyang Wang, Ling Li, Zhihui Zhang, Jing Jin1, Deyu Wu1, Yi Dong, Heng Xu*, Duo Lu *, Xiaoguang Chen*. 2021 online
2. Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. Kehui Zhang*, Ming Ji*, Songwen Lin, Shouguo Peng, Zhihui Zhang, Mingyi Zhang, Jingbo Zhang,Yan Zhang, Deyu Wu, Hua Tian, Xiaoguang Chen and Heng Xu. J. Med. Chem. 2021 online.
3. Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis. Jin J*, Ji M*, Fu R, Wang M, Xue N, Xiao Q, Hu J, Wang X, Lai F, Yin D, Chen X. Front Pharmacol. 2019.
4. CAT3, a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O6-methylguanine DNA methyltransferase expression. Ji M, Wang L, Chen J, Xue N, Wang C, Lai F, Wang R, Yu S, Jin J, Chen X. Onco Targets Ther. 2018, 11:3671-3684.
5. The Development of a Biotinylated NAD+-Applied Human Poly(ADP-Ribose) Polymerase 3 (PARP3) Enzymatic Assay. Ji M*, Wang L*, Xue N, Lai F, Zhang S, Jin J, Chen X. SLAS Discov. 2018.
6. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. Jie Zhou*, Ming Ji*, Haiping Yao, Ran Cao, Hailong Zhao, Xiaoyu Wang, Xiaoguang Chen and Bailing Xu. Org Biomol Chem. 2018.
7. Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment. Ji M*, Xue N, Lai F, Zhang X, Zhang S, Wang Y, Jin J, Chen X. Biol Pharm Bull. 2018.
8. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. Zhou Q*, Ji M*, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X. Biochem Pharmacol. 2016.
9. Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors. Zhao H*, Ji M*, Cui G, Zhou J, Lai F, Chen X, Xu B. Bioorg Med Chem. 2017.
10. Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. Zhou J*, Ji M*, Zhu Z, Cao R, Chen X, Xu B. Eur J Med Chem. 2017.
11. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. Yao H*, Ji M*, Zhu Z, Zhou J, Cao R, Chen X, Xu B. Bioorg Med Chem. 2015.

1. 溴代苄醚衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,张莉婧,杨阳,来芳芳,季鸣,周川,郑义,薛妮娜,李凌。中国专利号ZL2017800319432，授权公告日 2021/5/4
2. 一类抗肿瘤天然产物ecteinascidins结构类似物的制备和医药用途。刘站柱,陈晓光,鲁向冉,潘璇,季鸣,贯宝和。中国专利号ZL2018102983674，授权公告日 2021/4/13
3. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。美国专利号US10975049B2，授权公告日 2021/4/13
4. 含有哌嗪酮的喹唑啉酮类PARP-1/2抑制剂及其制作方法、药物组合物和用途。徐柏玲、陈晓光、周洁、季鸣、姚海平、周秦。中国专利号ZL201610108263.3， 授权公告日 2020/7/14
5. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。俄罗斯专利号RU2735541C2， 授权公告日 2020/11/3